RU2015155552A - Путеспецифические способы прогнозирования диагноза синдрома раздраженного кишечника - Google Patents
Путеспецифические способы прогнозирования диагноза синдрома раздраженного кишечника Download PDFInfo
- Publication number
- RU2015155552A RU2015155552A RU2015155552A RU2015155552A RU2015155552A RU 2015155552 A RU2015155552 A RU 2015155552A RU 2015155552 A RU2015155552 A RU 2015155552A RU 2015155552 A RU2015155552 A RU 2015155552A RU 2015155552 A RU2015155552 A RU 2015155552A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- group
- acid
- antibody
- biomolecule
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 4
- 238000003745 diagnosis Methods 0.000 title 1
- 230000000968 intestinal effect Effects 0.000 title 1
- 208000011580 syndromic disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 53
- WJXSWCUQABXPFS-UHFFFAOYSA-N 3-hydroxyanthranilic acid Chemical compound NC1=C(O)C=CC=C1C(O)=O WJXSWCUQABXPFS-UHFFFAOYSA-N 0.000 claims 20
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 claims 20
- 239000012634 fragment Substances 0.000 claims 20
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 18
- 125000003368 amide group Chemical group 0.000 claims 18
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 18
- 239000000427 antigen Substances 0.000 claims 16
- 102000036639 antigens Human genes 0.000 claims 16
- 108091007433 antigens Proteins 0.000 claims 16
- 230000027455 binding Effects 0.000 claims 16
- 230000009260 cross reactivity Effects 0.000 claims 15
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 claims 14
- -1 amidoalkyl Chemical group 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 13
- HCZHHEIFKROPDY-UHFFFAOYSA-N kynurenic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC(=O)C2=C1 HCZHHEIFKROPDY-UHFFFAOYSA-N 0.000 claims 12
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 9
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims 9
- 125000003435 aroyl group Chemical group 0.000 claims 9
- 229960002685 biotin Drugs 0.000 claims 9
- 235000020958 biotin Nutrition 0.000 claims 9
- 239000011616 biotin Substances 0.000 claims 9
- 125000001589 carboacyl group Chemical group 0.000 claims 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 9
- 230000002163 immunogen Effects 0.000 claims 9
- 239000002207 metabolite Substances 0.000 claims 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 9
- GJAWHXHKYYXBSV-UHFFFAOYSA-N quinolinic acid Chemical compound OC(=O)C1=CC=CN=C1C(O)=O GJAWHXHKYYXBSV-UHFFFAOYSA-N 0.000 claims 9
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 claims 9
- VCKPUUFAIGNJHC-UHFFFAOYSA-N 3-hydroxykynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC(O)=C1N VCKPUUFAIGNJHC-UHFFFAOYSA-N 0.000 claims 8
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 8
- JFWYSGGSCOOBGK-UHFFFAOYSA-N [3-(2-azaniumylethyl)-1h-indol-5-yl] sulfate Chemical compound C1=C(OS(O)(=O)=O)C=C2C(CCN)=CNC2=C1 JFWYSGGSCOOBGK-UHFFFAOYSA-N 0.000 claims 8
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 8
- RVWZUOPFHTYIEO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Natural products C1=C(O)C=C2C(C(=O)O)=CNC2=C1 RVWZUOPFHTYIEO-UHFFFAOYSA-N 0.000 claims 7
- 239000003310 5-hydroxyindoleacetic acid Substances 0.000 claims 7
- 239000002253 acid Substances 0.000 claims 6
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 claims 4
- 229940000681 5-hydroxytryptophan Drugs 0.000 claims 4
- IOIZWEJGGCZDOL-RQDYSCIWSA-N 7alpha-hydroxycholest-4-en-3-one Chemical class C([C@H]1O)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 IOIZWEJGGCZDOL-RQDYSCIWSA-N 0.000 claims 4
- 235000019260 propionic acid Nutrition 0.000 claims 4
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 3
- 230000009870 specific binding Effects 0.000 claims 3
- 125000004103 aminoalkyl group Chemical group 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 229940076279 serotonin Drugs 0.000 claims 2
- KCWQSNFJXVMEQC-UHFFFAOYSA-N 2-(5-hydroxy-1h-indol-2-yl)acetic acid Chemical class OC1=CC=C2NC(CC(=O)O)=CC2=C1 KCWQSNFJXVMEQC-UHFFFAOYSA-N 0.000 claims 1
- OYXZMSRRJOYLLO-RVOWOUOISA-N 7alpha-hydroxycholesterol Chemical compound C([C@H]1O)=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 OYXZMSRRJOYLLO-RVOWOUOISA-N 0.000 claims 1
- GDRFVCZRTJHPIY-UHFFFAOYSA-N NC1=C(O)C=CC=C1C(O)=O.OC(=O)C1=CC=CN=C1C(O)=O Chemical compound NC1=C(O)C=CC=C1C(O)=O.OC(=O)C1=CC=CN=C1C(O)=O GDRFVCZRTJHPIY-UHFFFAOYSA-N 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Computational Biology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361827506P | 2013-05-24 | 2013-05-24 | |
| US61/827,506 | 2013-05-24 | ||
| PCT/IB2014/061634 WO2014188377A2 (en) | 2013-05-24 | 2014-05-22 | Pathway specific assays for predicting irritable bowel syndrome diagnosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015155552A true RU2015155552A (ru) | 2017-06-27 |
Family
ID=50884973
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015155552A RU2015155552A (ru) | 2013-05-24 | 2014-05-22 | Путеспецифические способы прогнозирования диагноза синдрома раздраженного кишечника |
| RU2015155590A RU2015155590A (ru) | 2013-05-24 | 2014-05-22 | Путеспецифичные маркеры для диагностики синдрома раздраженного кишечника |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015155590A RU2015155590A (ru) | 2013-05-24 | 2014-05-22 | Путеспецифичные маркеры для диагностики синдрома раздраженного кишечника |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US9739786B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3004892B1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP2016521683A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20160010621A (cg-RX-API-DMAC7.html) |
| CN (2) | CN105392780A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2014269961A1 (cg-RX-API-DMAC7.html) |
| BR (2) | BR112015029318A2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2913108A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1223361A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL242597B (cg-RX-API-DMAC7.html) |
| MX (1) | MX367046B (cg-RX-API-DMAC7.html) |
| RU (2) | RU2015155552A (cg-RX-API-DMAC7.html) |
| SG (2) | SG11201509371XA (cg-RX-API-DMAC7.html) |
| WO (2) | WO2014188377A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105392780A (zh) * | 2013-05-24 | 2016-03-09 | 雀巢产品技术援助有限公司 | 用于预测肠易激综合征诊断的途径特异性测定 |
| CN105636601A (zh) | 2013-06-21 | 2016-06-01 | 翁德克控股有限公司 | 免疫治疗组合物及其用途 |
| WO2015169966A2 (en) * | 2014-05-09 | 2015-11-12 | Nogra Pharma Limited | Methods for treating inflammatory bowel disease |
| KR20170080701A (ko) | 2014-11-19 | 2017-07-10 | 네스텍 소시에테아노님 | 세로토닌, 트립토판 및 키누레닌 대사산물에 대한 항체 및 그의 용도 |
| BR112017010319B1 (pt) | 2014-11-19 | 2023-04-11 | NZP UK Limited | Esteroides 6-alquil-7-hidróxi-4-en-3-ona e processo para a preparação dos mesmos |
| PL3221332T3 (pl) | 2014-11-19 | 2019-10-31 | Nzp Uk Ltd | Steroidy, 5.beta.-6-alkilo-7-hydroksy-3-ony jako związki pośrednie do wytwarzania steroidowych modulatorów fxr |
| DK3221333T3 (da) | 2014-11-19 | 2019-09-30 | Nzp Uk Ltd | 6-alfa-alkyl-3,7-dionsteroider som mellemprodukter til fremstilling af steroide FXR-modulatorer |
| WO2016079520A1 (en) | 2014-11-19 | 2016-05-26 | Dextra Laboratories Limited | 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators |
| WO2016088068A1 (en) * | 2014-12-02 | 2016-06-09 | Nestec S.A. | Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease |
| CN105987995A (zh) * | 2015-02-04 | 2016-10-05 | 东莞博捷生物科技有限公司 | 一种检测人抗酿酒酵母IgG类抗体的酶联免疫试剂盒 |
| CN105987996A (zh) * | 2015-02-09 | 2016-10-05 | 东莞博捷生物科技有限公司 | 一种检测人抗酿酒酵母IgA类抗体的酶联免疫试剂盒 |
| CN105061305A (zh) * | 2015-08-31 | 2015-11-18 | 河南师范大学 | 一步合成3-甲基-2-吡啶甲酸甲酯的方法 |
| GB201608777D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Compounds |
| CN106399344B (zh) * | 2016-06-01 | 2021-01-01 | 上海领潮生物新材料有限公司 | 一种vin-cdtb融合蛋白的制备方法 |
| WO2018011691A1 (en) * | 2016-07-12 | 2018-01-18 | Nestec S.A. | Competitive immunoassay methods |
| CN106188191A (zh) * | 2016-07-13 | 2016-12-07 | 西安电子科技大学 | 基于gsh响应的诊治一体化有机分子探针及其制备方法 |
| US11959125B2 (en) | 2016-09-15 | 2024-04-16 | Sun Genomics, Inc. | Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample |
| US10428370B2 (en) | 2016-09-15 | 2019-10-01 | Sun Genomics, Inc. | Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample |
| CA3036702A1 (en) * | 2016-09-15 | 2018-03-22 | Sun Genomics Inc. | Universal method for extracting nucleic acid molecules from a diverse population of one or more types of microbes in a sample |
| US20180193003A1 (en) | 2016-12-07 | 2018-07-12 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| WO2018112237A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor |
| EP3554345A1 (en) | 2016-12-14 | 2019-10-23 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor |
| WO2018112215A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
| US11978543B2 (en) | 2016-12-14 | 2024-05-07 | Astarte Medical Partners Inc. | System and methods for developing and using a microbiome-based action component |
| EP4190318A1 (en) | 2016-12-14 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices |
| US11523772B2 (en) | 2016-12-14 | 2022-12-13 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immunosuppressant |
| WO2018112256A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor |
| WO2018112264A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| CN118873822A (zh) | 2016-12-14 | 2024-11-01 | 比奥拉治疗股份有限公司 | 使用tnf抑制剂治疗胃肠道疾病 |
| CA3046019A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a tlr modulator |
| WO2018112209A1 (en) * | 2016-12-14 | 2018-06-21 | Warren Tracy | System and methods for developing and using a microbiome-based action component for patient health |
| MX2019006823A (es) | 2016-12-14 | 2019-10-21 | Progenity Inc | Tratamiento de una enfermedad del tracto gastrointestinal con inhibidor de interleucina-12/interleucina-23 (il-12/il-23) liberado usando un dispositivo ingerible. |
| WO2018183931A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist |
| WO2018183932A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor |
| AU2018244922A1 (en) | 2017-03-30 | 2019-09-12 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with live biotherapeutics |
| EP3600416B1 (en) | 2017-03-30 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| US20200094031A1 (en) | 2017-03-30 | 2020-03-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor |
| WO2019036363A1 (en) | 2017-08-14 | 2019-02-21 | Progenity Inc. | TREATMENT OF GASTROINTESTINAL TRACT DISEASE WITH GLATIRAMER OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF |
| EP3750168B1 (en) * | 2018-02-09 | 2025-11-19 | Metabolomic Diagnostics Limited | A system and method of generating a model to detect, or predict the risk of, an outcome |
| US20210041460A1 (en) * | 2018-03-19 | 2021-02-11 | Fujifilm Wako Pure Chemical Corporation | Method for judging psychiatric disorder |
| CN112020651A (zh) * | 2018-04-24 | 2020-12-01 | 根特大学 | 用于家禽肠道健康的肠道和粪便生物标志物 |
| CN112400024B (zh) | 2018-06-01 | 2024-04-09 | 比奥拉治疗股份有限公司 | 用于胃肠道微生物组检测和处理的装置和系统 |
| CN112236831A (zh) * | 2018-06-07 | 2021-01-15 | 4D制药有限公司 | 用于对ibs患者分层的方法 |
| CN110607335B (zh) * | 2018-06-14 | 2021-08-03 | 中国科学院微生物研究所 | 一种烟酰胺腺嘌呤二核苷酸类化合物生物合成方法 |
| CN109324132A (zh) * | 2018-10-31 | 2019-02-12 | 杭州佰辰医学检验所有限公司 | 高通量检测色氨酸及其代谢产物的试剂盒及其应用 |
| US11488699B1 (en) | 2018-12-09 | 2022-11-01 | Cerner Innovation, Inc. | Microbiota activity sensor and decision support tool |
| US11842795B1 (en) * | 2018-12-17 | 2023-12-12 | Cerner Innovation, Inc. | Irritable bowel syndrome diagnostic sensor and decision support tool |
| FR3094492A1 (fr) * | 2019-04-01 | 2020-10-02 | Polyneuros | Procédé de détection ou de suivi de l’évolution d’une maladie chronique dégénérative par dosage immunologique |
| CN114040986A (zh) * | 2019-04-03 | 2022-02-11 | 4D制药科克有限公司 | 诊断疾病的方法 |
| JPWO2020213732A1 (ja) * | 2019-04-18 | 2021-04-30 | 株式会社サイキンソー | 過敏性腸症候群の検査方法 |
| US11884958B2 (en) * | 2019-04-30 | 2024-01-30 | Mayo Foundation For Medical Education And Research | Assessing and treating functional gastrointestinal disorders |
| AU2020275413A1 (en) | 2019-05-14 | 2021-12-23 | Cedars-Sinai Medical Center | TL1A patient selection methods, systems, and devices |
| WO2020232262A1 (en) * | 2019-05-16 | 2020-11-19 | Procisedx Inc. | Assay detection methods for vcam-1 and calprotectin |
| CN111351870A (zh) * | 2019-12-03 | 2020-06-30 | 康美华大基因技术有限公司 | 一种肠易激综合征血清代谢标记物组合及其诊断试剂盒 |
| EP4085256B1 (en) | 2020-01-27 | 2024-01-24 | Immundiagnostik AG | Test and in vitro diagnosis of irritable bowel syndrome |
| WO2021152586A1 (en) * | 2020-01-30 | 2021-08-05 | Yeda Research And Development Co. Ltd. | Methods of analyzing microbiome, immunoglobulin profile and physiological state |
| EP3913371A1 (en) | 2020-05-18 | 2021-11-24 | Neuroimmun GmbH | Method and kit for diagnosting irritable bowel syndrome and for its relief through dietary interventions |
| KR102478205B1 (ko) * | 2020-09-24 | 2022-12-15 | 경희대학교 산학협력단 | 크론병 환자에서 상부위장관 침범 진단을 위한 정보 제공 방법 |
| CN114755313B (zh) * | 2021-01-08 | 2024-08-30 | 复旦大学附属华山医院 | 包含尿液nad+代谢物的急性肾损伤标志物 |
| CN115724779B (zh) * | 2021-09-01 | 2024-03-29 | 四川大学 | 酰胺烷二硫化合物、其制备方法和用途 |
| JP2025500321A (ja) * | 2021-12-24 | 2025-01-09 | クレオン リミティド ライアビリティ カンパニー | 多脚型セロトニン作動性化合物ならびにセロトニン受容体アゴニスト及びアンタゴニストのプロドラッグ |
| WO2023180899A1 (en) * | 2022-03-21 | 2023-09-28 | Swain Manish Kumar | Device and method for detecting diarrhea |
| CN116381222A (zh) * | 2023-03-23 | 2023-07-04 | 北京巴瑞医疗器械有限公司 | 一种血清素发光免疫检测方法及血清素检测试剂盒 |
| CN116990498B (zh) * | 2023-09-28 | 2024-08-09 | 山东大学齐鲁医院 | 血浆色氨酸代谢物在儿童偏头痛诊断中的应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| ATE295420T1 (de) | 1992-02-06 | 2005-05-15 | Chiron Corp | Marker für krebs und biosynthetisches bindeprotein dafür |
| WO1994004690A1 (en) | 1992-08-17 | 1994-03-03 | Genentech, Inc. | Bispecific immunoadhesins |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6218129B1 (en) * | 1998-05-15 | 2001-04-17 | Prometheus Laboratories, Inc. | Inflammatory bowel disease first step assay system |
| US6406862B1 (en) | 1998-10-06 | 2002-06-18 | The United States Of America As Represented By The Secretary Of The Army | Dip-stick assay for C-reactive protein |
| AU784812B2 (en) * | 1999-12-15 | 2006-06-29 | Merck Sharp & Dohme Corp. | Lipopeptides as antibacterial agents |
| US6838250B2 (en) | 2000-03-31 | 2005-01-04 | Ortho-Clinical Diagnostics, Inc. | Immunoassay for C-reactive protein |
| DE10121217A1 (de) * | 2001-04-30 | 2002-10-31 | Merck Patent Gmbh | 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden |
| EP1687447A4 (en) | 2003-11-03 | 2008-04-02 | Univ Duke | METHOD FOR IDENTIFYING INDIVIDUALS IN THE HAZARD OF PERIOPERATIVE BLOODING, A KIDNEY PROBLEM OR A STROKE |
| US20060154276A1 (en) * | 2004-05-13 | 2006-07-13 | Prometheus Laboratories Inc. | Methods of diagnosing inflammatory bowel disease |
| US20060019410A1 (en) | 2004-07-21 | 2006-01-26 | Qualyst, Inc. | Apparatus, kits and methods for evaluating binding interactions, for detecting and quantifying binding molecules, and for sample preparation |
| WO2007000046A1 (en) * | 2005-06-27 | 2007-01-04 | Holburn Biomedical Corporation | Methods for diagnosing functional bowel disease |
| US7873479B2 (en) | 2005-12-01 | 2011-01-18 | Prometheus Laboratories Inc. | Methods of diagnosing inflammatory bowel disease |
| US20100094560A1 (en) | 2006-08-15 | 2010-04-15 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| US20080085524A1 (en) * | 2006-08-15 | 2008-04-10 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| US8278057B2 (en) | 2007-09-14 | 2012-10-02 | Nestec S.A. | Addressable antibody arrays and methods of use |
| US20120171672A1 (en) | 2009-04-14 | 2012-07-05 | Prometheus Laboratories Inc. | Inflammatory bowel disease prognostics |
| BRPI1013560A2 (pt) | 2009-04-14 | 2018-06-19 | Prometheus Laboratories Inc | métodos para auxiliar no prognóstico de doença instestinal inflamatória, e para predizer a probabilidade que um indivíduo diagnosticado com doença intestinal inflamatória responderá a um agente terapêutico de doença intestinal inflamatória |
| AU2010266028B2 (en) | 2009-06-25 | 2015-04-30 | Société des Produits Nestlé S.A. | Methods for diagnosing irritable bowel syndrome |
| WO2011053831A1 (en) * | 2009-10-30 | 2011-05-05 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| AU2010324735A1 (en) * | 2009-11-25 | 2012-07-12 | Nestec S.A. | Novel genomic biomarkers for irritable bowel syndrome diagnosis |
| US8445215B1 (en) * | 2010-07-23 | 2013-05-21 | Nestec S.A. | Assays and methods for the detection of Crohn's disease |
| EP2710383B1 (en) * | 2011-05-16 | 2017-01-11 | The University of Newcastle | Performance of a biomarker panel for irritable bowel syndrome |
| MX352274B (es) * | 2011-10-21 | 2017-11-16 | Nestec Sa | Metodos para mejorar el diagnostico de enfermedad inflamatoria intestinal. |
| WO2014053996A2 (en) | 2012-10-05 | 2014-04-10 | Nestec S.A. | Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for ibs |
| CN105392780A (zh) | 2013-05-24 | 2016-03-09 | 雀巢产品技术援助有限公司 | 用于预测肠易激综合征诊断的途径特异性测定 |
| TWI853985B (zh) * | 2013-12-04 | 2024-09-01 | 日商中外製藥股份有限公司 | 因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫 |
-
2014
- 2014-05-22 CN CN201480041536.6A patent/CN105392780A/zh active Pending
- 2014-05-22 HK HK16111564.5A patent/HK1223361A1/zh unknown
- 2014-05-22 CN CN201480041527.7A patent/CN105579852B/zh not_active Expired - Fee Related
- 2014-05-22 BR BR112015029318A patent/BR112015029318A2/pt not_active Application Discontinuation
- 2014-05-22 SG SG11201509371XA patent/SG11201509371XA/en unknown
- 2014-05-22 MX MX2015016196A patent/MX367046B/es active IP Right Grant
- 2014-05-22 CA CA2913108A patent/CA2913108A1/en not_active Abandoned
- 2014-05-22 WO PCT/IB2014/061634 patent/WO2014188377A2/en not_active Ceased
- 2014-05-22 AU AU2014269961A patent/AU2014269961A1/en not_active Abandoned
- 2014-05-22 EP EP14728346.9A patent/EP3004892B1/en not_active Not-in-force
- 2014-05-22 EP EP14731062.7A patent/EP3004068A2/en not_active Withdrawn
- 2014-05-22 CA CA2912993A patent/CA2912993A1/en not_active Abandoned
- 2014-05-22 AU AU2014269960A patent/AU2014269960B2/en not_active Ceased
- 2014-05-22 WO PCT/IB2014/061636 patent/WO2014188378A1/en not_active Ceased
- 2014-05-22 KR KR1020157036482A patent/KR20160010621A/ko not_active Ceased
- 2014-05-22 KR KR1020157036487A patent/KR20160013163A/ko not_active Ceased
- 2014-05-22 BR BR112015029320A patent/BR112015029320A8/pt not_active Application Discontinuation
- 2014-05-22 JP JP2016514523A patent/JP2016521683A/ja active Pending
- 2014-05-22 RU RU2015155552A patent/RU2015155552A/ru unknown
- 2014-05-22 JP JP2016514524A patent/JP2016520199A/ja active Pending
- 2014-05-22 SG SG11201509370UA patent/SG11201509370UA/en unknown
- 2014-05-22 RU RU2015155590A patent/RU2015155590A/ru not_active Application Discontinuation
-
2015
- 2015-11-11 US US14/938,729 patent/US9739786B2/en not_active Expired - Fee Related
- 2015-11-11 US US14/938,710 patent/US9891235B2/en not_active Expired - Fee Related
- 2015-11-15 IL IL242597A patent/IL242597B/en not_active IP Right Cessation
- 2015-11-15 IL IL242595A patent/IL242595B/en not_active IP Right Cessation
-
2017
- 2017-07-11 US US15/646,838 patent/US10036759B2/en active Active
- 2017-12-19 US US15/847,406 patent/US20180136233A1/en not_active Abandoned
-
2018
- 2018-06-29 US US16/024,183 patent/US10338083B2/en active Active
- 2018-08-09 AU AU2018214104A patent/AU2018214104A1/en not_active Abandoned
-
2019
- 2019-04-10 JP JP2019075081A patent/JP2019151637A/ja active Pending
- 2019-06-04 JP JP2019104805A patent/JP2019194600A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015155552A (ru) | Путеспецифические способы прогнозирования диагноза синдрома раздраженного кишечника | |
| JP2016521683A5 (cg-RX-API-DMAC7.html) | ||
| JP2017524725A5 (cg-RX-API-DMAC7.html) | ||
| JP2019506412A5 (cg-RX-API-DMAC7.html) | ||
| CN106443016B (zh) | 用于检测多特异性结合物的结合搭档的方法 | |
| JP2019523651A5 (cg-RX-API-DMAC7.html) | ||
| IL186948A0 (en) | Monoclonal antibodies and methods for their use in the detection of cervical disease | |
| JP2017532005A5 (cg-RX-API-DMAC7.html) | ||
| JP2018042573A5 (cg-RX-API-DMAC7.html) | ||
| JP2017518366A5 (cg-RX-API-DMAC7.html) | ||
| JP6203747B2 (ja) | 多特異性結合体の遊離結合パートナーの検出方法 | |
| RU2014149332A (ru) | Антитела против клаудина 18.2 для диагностики рака | |
| EA201100527A1 (ru) | Биологические продукты | |
| JP2013506428A5 (cg-RX-API-DMAC7.html) | ||
| JP2020516603A5 (cg-RX-API-DMAC7.html) | ||
| JP2005529587A5 (cg-RX-API-DMAC7.html) | ||
| JP2016505634A5 (cg-RX-API-DMAC7.html) | ||
| JP2015531768A5 (cg-RX-API-DMAC7.html) | ||
| EA200600646A1 (ru) | Способы, наборы и композиции для разработки и применения моноклональных антител, специфичных к антигенам с низкой иммуногенностью | |
| AU2015348940A1 (en) | Antibodies against serotonin, tryptophan and kynurenine metabolites and uses thereof | |
| JP2021100928A (ja) | シクロホスファミド及びイホスファミドのイムノアッセイ用の免疫原及びアッセイ接合体として用いるシクロホスファミド類似体 | |
| JP2018515071A5 (cg-RX-API-DMAC7.html) | ||
| RU2017114626A (ru) | Антитело, связывающее линейный эпитоп человеческого р53, и его применение в диагностике | |
| JP2014518624A5 (cg-RX-API-DMAC7.html) | ||
| ES2610471T3 (es) | Inmunoensayo para cannabinoides sintéticos basados en ciclopropilindol, metabolitos y derivados de los mismos |